Clinical Features and Outcomes of CBP Versus Non-CBP in Septic Children

计划入组 90 人 · 首次发布于 2021 年 3 月 12 日

Prulifloxacin in Chronic Bacterial Prostatitis (CBP)

计划入组 168 人 · 首次发布于 2017 年 6 月 28 日

A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis

计划入组 226 人 · 首次发布于 2020 年 6 月 24 日

EP300/CBPmodulators (Muhua Biotechnology)

CBP target protein degrader (EP300 mutated cancers )

CBP-8008

Check-Cap

CMP Therapeutics Ltd.

United Kingdom

CMP Development LLC

United States

Opna Bio Initiates Phase I Trial of OPN-6602 for Multiple Myeloma

Opna Bio's Zavabresib Receives FDA Orphan Drug Designation for Myelofibrosis Treatment

Foghorn Therapeutics Advances Oncology Programs Targeting Chromatin Dysregulation